Banlota, Daisy A.

HRN: 15-36-30  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/14/2024
CLINDAMYCIN 150MG/ML, 4ML (AMP)
07/14/2024
07/21/2024
IV
600mg
Q8h
Breast Mass, Invasive Ductal Carcinoma
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: